Search General Info
Search Education
Search Partnering Companies
Cellino Biotech, Inc.
9:15 AM - 9:30 AM (EST), Tuesday, February 7, 2023 ・ Music Box
![CEO 2023 Logo](/sites/default/files/2022-08/264423_BIO_22_CEO_Logo-V.png)
Cellino is building the leading precision platform to scale personalized stem cell-based therapies, with the goal of unlocking regenerative medicine for hundreds of millions of patients.
Cellino’s proprietary platform combines label-free imaging and high-speed laser editing with machine learning to automate cell reprogramming, expansion, and differentiation in a closed cassette format, enabling potentially thousands of patient samples to be processed in parallel in a single facility.
Stem cell-derived regenerative medicines are poised to cure some of the toughest diseases within this decade, including Parkinson’s, diabetes, age-related macular degeneration and heart disease. Patient-specific cells potentially provide the safest, most effective cures for these indications. Cellino’s vision is to make personalized regenerative medicines viable at large scale.
Cellino’s proprietary platform combines label-free imaging and high-speed laser editing with machine learning to automate cell reprogramming, expansion, and differentiation in a closed cassette format, enabling potentially thousands of patient samples to be processed in parallel in a single facility.
Stem cell-derived regenerative medicines are poised to cure some of the toughest diseases within this decade, including Parkinson’s, diabetes, age-related macular degeneration and heart disease. Patient-specific cells potentially provide the safest, most effective cures for these indications. Cellino’s vision is to make personalized regenerative medicines viable at large scale.
![](/sites/default/files/hubb_images/6588/attachments/%2520-%2520f1_Cellino_ce04f9ac.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
Technology platform to enable scaled development of stem cell-based therapies
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
![photo](/act-root/bio/assets/images/profile-default.png)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved